BRCA testing in unaffected young women in the United States, 2006-2017

Research output: Contribution to journalArticle

Abstract

Background: The discovery of the BRCA gene in the 1990s created an opportunity for individualized cancer prevention. BRCA testing in young women before cancer onset enables early detection of those with an increased cancer risk and creates an opportunity to offer lifesaving prophylactic procedures and medications. This study assessed trends in BRCA testing in women younger than 40 years without diagnosed breast or ovarian cancer (unaffected young women [UYW]) for cancer prevention between 2006 and 2017 in the United States. Methods: This study included 93,278 adult women 18 to 65 years old with insurance claims for BRCA testing between 2006 and 2017 from the de-identified Optum Clinformatics Data Mart database. The data contained medical claims and administrative information from privately insured individuals in the United States. The proportion of BRCA testing in UYW younger than 40 years among adult women aged 18 to 65 years who received BRCA testing was assessed. Results: In 2006, only 10.5% of the tests were performed in UYW. The proportion of BRCA tests performed in UYW increased significantly to 25.5% in 2017 (annual percentage change for the 2006-2017 period, 6.9; 95% confidence interval, 6.4-7.3; P <.001). The increased trend in the proportion of BRCA tests in UYW significantly differed by region of residence and family history of breast or ovarian cancer. Conclusions: Over the past decade, there was increased use of BRCA testing for cancer prevention. Additional efforts are needed to maximize the early detection of women with BRCA pathogenic variants so that these cancers may be prevented.

Original languageEnglish (US)
JournalCancer
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Neoplasms
Ovarian Neoplasms
Breast Neoplasms
Genetic Association Studies
Insurance
Databases
Confidence Intervals

Keywords

  • BRCA testing
  • breast cancer
  • mutation carrier
  • ovarian cancer
  • pathogenic variant carrier
  • primary prevention
  • unaffected

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{9e173784c154410789a836450f689119,
title = "BRCA testing in unaffected young women in the United States, 2006-2017",
abstract = "Background: The discovery of the BRCA gene in the 1990s created an opportunity for individualized cancer prevention. BRCA testing in young women before cancer onset enables early detection of those with an increased cancer risk and creates an opportunity to offer lifesaving prophylactic procedures and medications. This study assessed trends in BRCA testing in women younger than 40 years without diagnosed breast or ovarian cancer (unaffected young women [UYW]) for cancer prevention between 2006 and 2017 in the United States. Methods: This study included 93,278 adult women 18 to 65 years old with insurance claims for BRCA testing between 2006 and 2017 from the de-identified Optum Clinformatics Data Mart database. The data contained medical claims and administrative information from privately insured individuals in the United States. The proportion of BRCA testing in UYW younger than 40 years among adult women aged 18 to 65 years who received BRCA testing was assessed. Results: In 2006, only 10.5{\%} of the tests were performed in UYW. The proportion of BRCA tests performed in UYW increased significantly to 25.5{\%} in 2017 (annual percentage change for the 2006-2017 period, 6.9; 95{\%} confidence interval, 6.4-7.3; P <.001). The increased trend in the proportion of BRCA tests in UYW significantly differed by region of residence and family history of breast or ovarian cancer. Conclusions: Over the past decade, there was increased use of BRCA testing for cancer prevention. Additional efforts are needed to maximize the early detection of women with BRCA pathogenic variants so that these cancers may be prevented.",
keywords = "BRCA testing, breast cancer, mutation carrier, ovarian cancer, pathogenic variant carrier, primary prevention, unaffected",
author = "Fangjian Guo and Matthew Scholl and Fuchs, {Erika L.} and Berenson, {Abbey B.} and Kuo, {Yong Fang}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/cncr.32536",
language = "English (US)",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - BRCA testing in unaffected young women in the United States, 2006-2017

AU - Guo, Fangjian

AU - Scholl, Matthew

AU - Fuchs, Erika L.

AU - Berenson, Abbey B.

AU - Kuo, Yong Fang

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The discovery of the BRCA gene in the 1990s created an opportunity for individualized cancer prevention. BRCA testing in young women before cancer onset enables early detection of those with an increased cancer risk and creates an opportunity to offer lifesaving prophylactic procedures and medications. This study assessed trends in BRCA testing in women younger than 40 years without diagnosed breast or ovarian cancer (unaffected young women [UYW]) for cancer prevention between 2006 and 2017 in the United States. Methods: This study included 93,278 adult women 18 to 65 years old with insurance claims for BRCA testing between 2006 and 2017 from the de-identified Optum Clinformatics Data Mart database. The data contained medical claims and administrative information from privately insured individuals in the United States. The proportion of BRCA testing in UYW younger than 40 years among adult women aged 18 to 65 years who received BRCA testing was assessed. Results: In 2006, only 10.5% of the tests were performed in UYW. The proportion of BRCA tests performed in UYW increased significantly to 25.5% in 2017 (annual percentage change for the 2006-2017 period, 6.9; 95% confidence interval, 6.4-7.3; P <.001). The increased trend in the proportion of BRCA tests in UYW significantly differed by region of residence and family history of breast or ovarian cancer. Conclusions: Over the past decade, there was increased use of BRCA testing for cancer prevention. Additional efforts are needed to maximize the early detection of women with BRCA pathogenic variants so that these cancers may be prevented.

AB - Background: The discovery of the BRCA gene in the 1990s created an opportunity for individualized cancer prevention. BRCA testing in young women before cancer onset enables early detection of those with an increased cancer risk and creates an opportunity to offer lifesaving prophylactic procedures and medications. This study assessed trends in BRCA testing in women younger than 40 years without diagnosed breast or ovarian cancer (unaffected young women [UYW]) for cancer prevention between 2006 and 2017 in the United States. Methods: This study included 93,278 adult women 18 to 65 years old with insurance claims for BRCA testing between 2006 and 2017 from the de-identified Optum Clinformatics Data Mart database. The data contained medical claims and administrative information from privately insured individuals in the United States. The proportion of BRCA testing in UYW younger than 40 years among adult women aged 18 to 65 years who received BRCA testing was assessed. Results: In 2006, only 10.5% of the tests were performed in UYW. The proportion of BRCA tests performed in UYW increased significantly to 25.5% in 2017 (annual percentage change for the 2006-2017 period, 6.9; 95% confidence interval, 6.4-7.3; P <.001). The increased trend in the proportion of BRCA tests in UYW significantly differed by region of residence and family history of breast or ovarian cancer. Conclusions: Over the past decade, there was increased use of BRCA testing for cancer prevention. Additional efforts are needed to maximize the early detection of women with BRCA pathogenic variants so that these cancers may be prevented.

KW - BRCA testing

KW - breast cancer

KW - mutation carrier

KW - ovarian cancer

KW - pathogenic variant carrier

KW - primary prevention

KW - unaffected

UR - http://www.scopus.com/inward/record.url?scp=85073956685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073956685&partnerID=8YFLogxK

U2 - 10.1002/cncr.32536

DO - 10.1002/cncr.32536

M3 - Article

C2 - 31568561

AN - SCOPUS:85073956685

JO - Cancer

JF - Cancer

SN - 0008-543X

ER -